Cipla share price up 2% after associate firm submits application to USFDA for IV tramadol


Cipla share price added more than 2 percent in the morning trade on December 12 after the pharmaceutical major announced submission of application for intravenous (IV) tramadol with USFDA.

Avenue Therapeutics Inc submitted a new drug application to the United States Food and Drug Administration (USFDA) for IV tramadol for managing moderate to moderately severe pain in adults, the company said in a release.

The application is based on positive results from two Phase 3 clinical efficacy and safety trials in patients following bunionectomy and abdominoplasty surgeries, as well as an open-label safety study of more than 500 patients who received the 50 mg dosing regimen, it added.

At 0931 hours, Cipla was quoting at Rs 461.00, up Rs 11.30, or 2.51 percent, on the BSE.

News Source:- Moneycontrol

For Enquiry Fill The Form

*Note:- Please provide a valid Email Id to receive OTP from

Facebook Iconfacebook like buttonYouTube IconTwitter Icontwitter follow button